169 related articles for article (PubMed ID: 33389013)
1. Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Takamori S; Takada K; Shimokawa M; Jinnnouchi M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Takenoyama M; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
Cancer Immunol Immunother; 2021 Jun; 70(6):1745-1753. PubMed ID: 33389013
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Oh MS; Guzner A; Wainwright DA; Mohindra NA; Chae YK; Behdad A; Villaflor VM
Clin Lung Cancer; 2021 Jan; 22(1):e57-e62. PubMed ID: 32900613
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
[TBL] [Abstract][Full Text] [Related]
4. Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
Miyawaki T; Kenmotsu H; Mori K; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Harada H; Endo M; Ohde Y; Takahashi K; Takahashi T
Clin Lung Cancer; 2020 Sep; 21(5):e405-e414. PubMed ID: 32205040
[TBL] [Abstract][Full Text] [Related]
5. Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression.
Stinchcombe TE; Miksad RA; Gossai A; Griffith SD; Torres AZ
Clin Lung Cancer; 2020 Sep; 21(5):389-394.e3. PubMed ID: 32409266
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.
Gobbini E; Toffart AC; Pérol M; Assié JB; Duruisseaux M; Coupez D; Dubos C; Westeel V; Delaunay M; Guisier F; Veillon R; Gounant V; Giroux Leprieur E; Vanel FR; Chaabane N; Dansin E; Babey H; Decroisette C; Barlesi F; Daniel C; Fournel P; Mezquita L; Oulkhouir Y; Canellas A; Duchemann B; Molinier O; Alcazer V; Moro-Sibilot D; Levra MG
Clin Lung Cancer; 2020 Sep; 21(5):e497-e510. PubMed ID: 32605892
[TBL] [Abstract][Full Text] [Related]
7. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
Vergnenegre A; Geier M; Guisier F; Lamy R; Comet B; Le Garff G; Do P; Janicot H; Morel H; Decroisette C; Andre M; Falchero L; Paleiron N; Monnet I;
Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
[TBL] [Abstract][Full Text] [Related]
8. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
9. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
[TBL] [Abstract][Full Text] [Related]
10. The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors.
Takada K; Shimokawa M; Takamori S; Shimamatsu S; Hirai F; Ono Y; Tagawa T; Okamoto T; Hamatake M; Okamoto I; Mori M
PLoS One; 2022; 17(2):e0263247. PubMed ID: 35130287
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy.
Takamori S; Takada K; Shimokawa M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Takenoyama M; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
Int J Cancer; 2020 Oct; 147(8):2327-2334. PubMed ID: 32356560
[TBL] [Abstract][Full Text] [Related]
12. Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.
Zhang L; Bai L; Liu X; Liu Y; Li S; Liu J; Zhang S; Yang C; Ren X; Cheng Y
Thorac Cancer; 2020 May; 11(5):1170-1179. PubMed ID: 32134200
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M
Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
[TBL] [Abstract][Full Text] [Related]
14. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
Roch B; Coffy A; Jean-Baptiste S; Palaysi E; Daures JP; Pujol JL; Bommart S
Lung Cancer; 2020 May; 143():19-26. PubMed ID: 32200137
[TBL] [Abstract][Full Text] [Related]
15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
16. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
17. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy.
Sun L; Davis CW; Hwang WT; Jeffries S; Sulyok LF; Marmarelis ME; Singh AP; Berman AT; Feigenberg SJ; Levin W; Ciunci CA; Bauml JM; Cohen RB; Langer CJ; Aggarwal C
Clin Lung Cancer; 2021 Jan; 22(1):58-66.e3. PubMed ID: 33279417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
